GlaxoSmithKline (NYSE:GSK) shares move down as the firm withdraws a supplemental New Drug Application to the FDA for use of its Tykerb drug in unison with Genentech’s Herceptin for the treatment of a certain type of breast cancer in patients who have already received Herceptin. A spokesperson commented that, “Our discussions with FDA highlighted questions that could not be addressed with the data currently available.”
Investing Insights: J&J’s Second Quarter Earnings Sneak Peek.
Peregrine Pharmaceuticals (NASDAQ:PPHM) shares gain almost 25 percent Thursday, while CEO Steven King was due to make a presentation at the JMP Securities Healthcare Conference in New York. The firm announced positive results from a Phase IIb trial of its bavituximab lung cancer treatment.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.